A single agent Phase II study of depsipeptide (FK228) in the treatment of Cutaneous T-cell lymphoma To confirm the efficacy of FK228, depsipeptide, as reported in the Phase I and early Phase II studies, in patients with CTCL who are no longer controlled on skin-directed therapy and who have had at l...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

An exploratory Phase II, multicenter, open-label trial evaluating the activity and tolerability of of FK228 in androgen independent metastatic prostate cancer patients with a rising PSA The primary objective of this trial is to evaluate the activity of FK228 in patients with metastatic prostate cancer who have developed a rising PSA while undergoing hormonal therapy. Activity will b...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Gloucester GPI-06-0002 : Essai de phase 2 évaluant l’efficacité et la tolérance d’un traitement par romidepsin chez des patients ayant un lymphome. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] A phase II, multicenter, open-label trial evaluating the activity and tolerability of romidepsin (depsipeptide, FK228) in progressive or relapsed peripheral T-cell lymphoma following prior systemic th...

• Pays France
• Organes Leucémies aiguës
• Spécialités Chimiothérapie

A MULTICENTER, OPEN-LABEL CONTINUATION TRIAL EVALUATING THE TOLERABILITY AND ACTIVITY OF DEPSIPEPTIDE (FK228) IN PATIENTS THAT HAVE COMPLETED A PRIOR CLINICAL STUDY WITH DEPSIPEPTIDE The primary objective of this trial is to evaluate the safety and tolerability of extended treatment with depsipeptide in patients who have at least demonstrated stable disease on a prior Gloucester-s...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A PHASE II, MULTICENTER, OPEN-LABEL TRIAL EVALUATING THE ACTIVITY AND TOLERABILITY OF ROMIDEPSIN (DEPSIPEPTIDE, FK228) IN PROGRESSIVE OR RELAPSED PERIPHERAL T-CELL LYMPHOMA FOLLOWING PRIOR SYSTEMIC THERAPY The primary objective of this trial is to evaluate the activity of romidepsin in patients with progressive or relapsed PTCL following prior systemic therapy. The primary efficacy parameter is the rat...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune